<DOC>
	<DOCNO>NCT02598726</DOCNO>
	<brief_summary>This pilot phase I trial study side effect best dose curcumin give together piperine ( piperine extract [ standardize ] ) reduce inflammation ureteral stent-induced symptom patient cancer . Curcumin spice similar turmeric work decrease chemical moderator produce inflammation body . Piperine pepper work increase amount curcumin available body take curcumin . Giving curcumin together piperine may reduce inflammation discomfort ureteric stent old patient cancer .</brief_summary>
	<brief_title>Curcumin Piperine Reducing Inflammation Ureteral Stent-Induced Symptoms Patients With Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To conduct dose-escalation study curcumin piperine derive safe , optimal biological dose combination cancer patient . SECONDARY OBJECTIVES : I . To describe grade 2+ toxicity associate curcumin piperine . II . To evaluate quality life associate combination mean Mayo Modified Urinary Stent Symptom Questionnaire ( USSQ ) . TERTIARY OBJECTIVES : I . To characterize change urinary prostaglandin E2 concentration occur baseline one week curcumin + piperine . OUTLINE : This dose-escalation study curcumin . Patients receive curcumin orally ( PO ) twice daily ( BID ) thrice daily ( TID ) piperine extract ( standardize ) PO day 1-7 absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Piperine</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Ureteral stent place study registration Patient report pain , spasm , urgency symptom stent placement , think unrelated cause per patient healthcare provider ( documentation medical record unnecessary ) Ability complete English language questionnaire assistance After weeklong study treatment , participant must willing return enrol institution followup visit Willingness provide mandatory 24 hour urine collection sample research purpose Able swallow supplement Patient must either history cancer active cancer Registration &gt; = 7 day placement new stent &gt; = 3 day stent exchange Willingness refrain grapefruit juice 7 day prior 7 day study Receiving warfarin registration Active cholecystitis Requires treatment nonsteroidal antiinflammatory agent stop one week study participation Taking follow drug time study participation : epidermal growth factor receptor inhibitor , topoisomerase 1 inhibitor ( camptothecin , irinotecan ) ; buspirone , benzodiazepine , zolpidem , calcium channel blocker ( felodipine , nifedipine , verapamil ) ; digoxin quinidine ; codeine fentanyl ; phenytoin , propranolol , rifampin , theophylline History alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>